184 related articles for article (PubMed ID: 6970630)
1. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Mitchell BS; Koller CA; Kelley WN
Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
[No Abstract] [Full Text] [Related]
3. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
[TBL] [Abstract][Full Text] [Related]
4. Clinical, pharmacologic, and immunologic effects of 2'-deoxycoformycin.
Cummings FJ; Crabtree GW; Wiemann MC; Spremulli EN; Parks RE; Calabresi P
Clin Pharmacol Ther; 1988 Nov; 44(5):501-9. PubMed ID: 3263248
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of deoxycoformycin.
Major PP; Agarwal RP; Kufe DW
Blood; 1981 Jul; 58(1):91-6. PubMed ID: 6263381
[TBL] [Abstract][Full Text] [Related]
6. Low-dose deoxycoformycin in lymphoid malignancy.
Grever MR; Leiby JM; Kraut EH; Wilson HE; Neidhart JA; Wall RL; Balcerzak SP
J Clin Oncol; 1985 Sep; 3(9):1196-201. PubMed ID: 2993534
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic conversion of acute leukaemia from T-lymphoblastic to myeloblastic induced by therapy with 2'-deoxycoformycin.
Murphy SB; Stass S; Kalwinsky D; Rivera G
Br J Haematol; 1983 Oct; 55(2):285-93. PubMed ID: 6604543
[TBL] [Abstract][Full Text] [Related]
8. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.
Dillman RO; Mick R; McIntyre OR
J Clin Oncol; 1989 Apr; 7(4):433-8. PubMed ID: 2784491
[TBL] [Abstract][Full Text] [Related]
9. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
Kefford RF; Fox RM
Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
[No Abstract] [Full Text] [Related]
10. Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.
Yamaguchi K; Yul LS; Oda T; Maeda Y; Ishii M; Fujita K; Kagiyama S; Nagai K; Suzuki H; Takatsuki K
Leuk Res; 1986; 10(8):989-93. PubMed ID: 3489140
[TBL] [Abstract][Full Text] [Related]
11. Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
Macdonald JS; Marsoni S; Bruno S; Poster D
Recent Results Cancer Res; 1982; 80():323-30. PubMed ID: 6977170
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.
Poplack DG; Sallan SE; Rivera G; Holcenberg J; Murphy SB; Blatt J; Lipton JM; Venner P; Glaubiger DL; Ungerleider R; Johns D
Cancer Res; 1981 Sep; 41(9 Pt 1):3343-6. PubMed ID: 6973390
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
Prentice HG; Russell NH; Lee N; Ganeshaguru K; Blacklock H; Piga A; Smyth JF; Hoffbrand AV
Lancet; 1981 Dec; 2(8258):1250-4. PubMed ID: 6118669
[TBL] [Abstract][Full Text] [Related]
14. An enzymatic kinetic method for the determination of 2'-deoxycoformycin in biological fluids.
Staubus AE; Weinrib AB; Malspeis L
Biochem Pharmacol; 1984 May; 33(10):1633-7. PubMed ID: 6610419
[TBL] [Abstract][Full Text] [Related]
15. Adenosine deaminase in malaria infection: effect of 2'-deoxycoformycin in vivo.
Webster HK; Wiesmann WP; Pavia CS
Adv Exp Med Biol; 1984; 165 Pt A():225-9. PubMed ID: 6609525
[No Abstract] [Full Text] [Related]
16. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
[No Abstract] [Full Text] [Related]
17. Transport of deoxycoformycin in human erythrocytes. Measurement by adenosine deaminase titration and radioisotope assays.
Chen SF; Stoeckler JD; Parks RE
Biochem Pharmacol; 1984 Dec; 33(24):4069-79. PubMed ID: 6334522
[TBL] [Abstract][Full Text] [Related]
18. Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes.
Kefford RF; Fox RM
Br J Haematol; 1982 Apr; 50(4):627-36. PubMed ID: 6978147
[TBL] [Abstract][Full Text] [Related]
19. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
[TBL] [Abstract][Full Text] [Related]
20. Deoxycoformycin in the treatment of leukemias and lymphomas.
Smyth JF; Prentice HG; Proctor S; Hoffbrand AV
Ann N Y Acad Sci; 1985; 451():123-8. PubMed ID: 3878113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
